PHARMACIA & UPJOHN XALATAN RISK OF IRIDIAL PIGMENTATION TO BE ASSESSED IN FOUR POST-MARKETING STUDIES; APPROVAL RECOMMENDED BY FDA ADVISORY COMMITTEE
Executive Summary
Pharmacia & Upjohn will assess the risk of iridial pigmentation associated with administration of its glaucoma therapy Xalatan (latanoprost) in four post-marketing studies, the company reported during a Dec. 9 review of the topical prostaglandin by FDA's Ophthalmic Drugs Subcommittee.